[1]罗明志,陈鹤升,周远群,等.全球结核病疫情与诊断新技术[J].常州大学学报(自然科学版),2016,(06):18-22.[doi:10.3969/j.issn.2095-0411.2016.06.004]
　LUO Mingzhi,CHEN Hesheng,ZHOU Yuanqun,et al.Global Tuberculosis Epidemic and New Diagnosis Technology[J].Journal of Changzhou University(Natural Science Edition),2016,(06):18-22.[doi:10.3969/j.issn.2095-0411.2016.06.004]
点击复制

全球结核病疫情与诊断新技术()
分享到：

常州大学学报(自然科学版)[ISSN:2095-0411/CN:32-1822/N]

卷:
期数:
2016年06期
页码:
18-22
栏目:
生物医学工程
出版日期:
2016-11-30

文章信息/Info

Title:
Global Tuberculosis Epidemic and New Diagnosis Technology
作者:
罗明志; 陈鹤升; 周远群; 高海洋; 金阳; 李琳; 邓林红
常州大学 生物医学工程与健康科学研究院,常州市呼吸医学工程重点实验室,江苏 常州 213164
Author(s):
LUO Mingzhi;  CHEN Hesheng;  ZHOU Yuanqun;  GAO Haiyang;  JIN Yang;  LI Lin;  DENG Linhong
Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of Biomedical Engineering and Health Sciences, Changzhou University, Changzhou 213164, China
关键词:
结核病;  疫情;  防治;  诊断技术
Keywords:
Tuberculosis;  epidemic;  prevention and control;  diagnosis
分类号:
R 441
DOI:
10.3969/j.issn.2095-0411.2016.06.004
文献标志码:
A
摘要:
结核病是全世界重点防控的一类传染病。全球结核病在1993年进入紧急状态,随着“千年发展目标”结核病防控战略的实施,全球结核病防控取得了巨大进展。2016年,全球进入“结核病终止策略”新阶段,这对结核病的诊断,尤其是潜伏性感染诊断和耐药结核诊断提出了更高的要求。概述了全球结核病疫情和防控情况,并对相关诊断技术的进行了比较,为今后结核病的精准防控提供参考。
Abstract:
As one of the infectious diseases, much focus is laid on the prevention, diagnosis and treatment of Tubercnlosis(TB)all over the world. Global TB infection was in a state of emergency in 1993, but with the implementation of “Millennium Development Goals”, great progress has been made in global TB prevention and control. In 2016, the world comes into a new stage of "The END TB Strategy ", and this puts forward higher requirements for the diagnosis of tuberculosis, especially for latent infection diagnosis and drug-resistant TB. This paper first summarizes the global TB epidemic and control situation, and compares the latest development of diagnostic technology, providing a reference for the further accurate early prevention and control of TB.

参考文献/References:

[1]PAI M, SCHITO M. Tuberculosis diagnostics in 2015: Landscape, priorities, needs, and prospects[J]. Journal of Infectious Diseases, 2015, 211(suppl2): 21-28.
[2] PRASAA A, ROSS A, ROSENBERG P, et al. A world of cities and the end of TB[J]. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110(3):151-152.
[3] UPLEKAR M, WEIL D, LONNROTH K, et al. WHO’s new End TB strategy[J]. The Lancet, 2015, 385(9979): 1799-1801.
[4] CHEON S A, CHO H H, KIM J, et al. Recent tuberculosis diagnosis toward the end TB strategy[J]. Journal of Microbiological Methods, 2016, 123: 51-61.
[5] RAVIGLIONE M C, UPLEKAR M W. WHO’s new stop TB strategy[J]. The Lancet, 2006, 367(9514): 952-955.
[6] HUYNH G H. Can China achieve the WHO global targets for TB control by 2035[J]. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110(3): 161-162.
[7] DENG J, BI L, ZHOU L, et al. Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity[J]. Cell Reports, 2014, 9(6): 2317-2329.
[8] LALVANI A, PAREEK M. A 100 year update on diagnosis of tuberculosis infection[J]. British Medical Bulletin, 2010, 93(1): 69-84.
[9] ROBERTS C A. Old world tuberculosis: Evidence from human remains with a review of current research and future prospects. Tuberculosis, 2015, 95(Suppl 1): 117-121.
[10] EVANS C A. GeneXpert-A game-changer for tuberculosis control[J]. PLoS Medicine, 2011, 8: e1001064.
[11] DORMAN S E. New diagnostic tests for tuberculosis: Bench, bedside, and beyond[J]. Clinical Infectious Diseases, 2010, 50(suppl3): 173-177.
[12] WINETSKY D E, NEGOESCU D M, DEMARCHIS E H, et al. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: A cost-effectiveness analysis[J]. PLoS Medicine, 2012, 9(11): e1001348.
[13] WHITWORTH H S, SCOTT M, CONNELL D W, et al. IGRAs-the gateway to T cell based TB diagnosis[J]. Methods, 2013,61(1): 52-62.
[14] SINGH N, SREENIVAS V, SHEORAN A, et al. Serodiagnostic potential of immuno-PCR using a cocktail of mycobacterial antigen 85B, ESAT-6 and cord factor in tuberculosis patients[J]. Journal of Microbiological Methods, 2016, 120: 56-64.
[15] Redelman-SIDI G, SEPKOWITZ K A. IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults[J]. American Journal of Respiratory and Critical Care Medicine, 2013, 188(4): 422-431.
[16] DIEL R, LODDENKEMPER R, NIENHAUS A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state[J]. Chest, 2012, 142(1): 63-75.
[17] PAI M, ZWERLING A, MENZIES D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update[J]. Annals of Internal Medicine, 2008, 149(3): 177-184.
[18] ABUBAKAR I, STAGG H R, WHITWORTH H, et al. How should I interpret an interferon gamma release assay result for tuberculosis infection[J]. Thorax, 2013, 68(3): 298-301.
[19] ATRE S. An urgent need for building technical capacity for rapid diagnosis of multidrug-resistant tuberculosis(MDR-TB)among new cases: a case report from Maharashtra, India[J]. Journal of Infection and Public Health, 2015, 8(5): 502-505.
[20] YAN L, XIAO H, ZHANG Q. Systematic review: Comparison of Xpert MTB/RIF, LAMP and SAT methods for the diagnosis of pulmonary tuberculosis[J]. Tuberculosis(Edinburgh, Scotland), 2016, 96: 75-86.
[21] STEINGART K R, SCHILLER I, HORNE D J, et al. Xpert(R)MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults[J]. The Cochrane Database of Systematic Reviews, 2014(1): CD009593.

备注/Memo

备注/Memo:
收稿日期:2016-06-02。基金项目:国家自然科学基金重点项目(11532003); 江苏省高校自然科学研究面上项目(14KJB180001); 常州市应用基础项目(CJ20159033)。作者简介:罗明志(1980—),男,湖北随州人,博士,讲师,主要从事细胞生物学研究。通讯联系人:邓林红(1960—),E-mail: dlh@cczu.edu.cn
更新日期/Last Update: 2016-11-20